Disease prediction with multi-omics and biomarkers empowers case–control genetic discoveries in the UK Biobank
Manik Garg(AstraZeneca (United Kingdom)), Dimitrios Vitsios(AstraZeneca (United Kingdom)), Fengyuan Hu(Babraham Institute), Katherine R. Smith(Murdoch Children's Research Institute), Marcin Karpiński(AstraZeneca (United Kingdom)), Oliver S. Burren(AstraZeneca (United Kingdom)), Andrew R. Harper(AstraZeneca (United Kingdom)), Eleanor Wheeler(AstraZeneca (United Kingdom)), Ryan S. Dhindsa(Baylor College of Medicine), Jonathan Mitchell(AstraZeneca (United Kingdom)), Margarete A. Fabre(AstraZeneca (United Kingdom)), Euan A. Ashley(Stanford University), Slavé Petrovski(The Royal Melbourne Hospital), Amanda O’Neill(University of Cambridge), Dorota Matelska(International Institute of Molecular and Cell Biology), Quanli Wang(AstraZeneca (United States)), Lawrence Middleton(AstraZeneca (United Kingdom))
Cited by 98
Related Papers
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
|Nature Genetics|2007|1.5k
Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters
|Cell|2016|1.2k